Featured Research

from universities, journals, and other organizations

New twist in diabetes drugs could reduce life-threatening side effects

Date:
September 9, 2011
Source:
Dana-Farber Cancer Institute
Summary:
Researchers have created prototype drugs that have powerful anti-diabetic effects and are free of dangerous side effects plaguing some current diabetes medications.

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free -- at least in mice -- of dangerous side effects plaguing some current diabetes medications.

The researchers say that their "proof-of-principle" findings could lead to safer medications for Type 2 diabetes, which affects more than 25 million children and adults in the United States. Their findings are being published Sept. 4 by the journal Nature as an advanced online publication and later in a print edition.

One of the drug prototypes proved capable of reducing disease symptoms in diabetes-prone mice without triggering weight gain or fluid retention, potential side effects of current drugs such as rosiglitazone (Avandia) and pioglitazone (Actos) that can have had fatal consequences in some patients.

Bruce Spiegelman, PhD, of Dana-Farber and Patrick Griffin, PhD, of Scripps led the scientific group that developed a series of related compounds and tested them in overfed and genetically obese mice. While these novel compounds would not be suitable for use in human patients, the scientists say the results showed that they had succeeded in building selective anti-diabetic molecules that minimize the risk of severe side effects.

"This insight shows how you can make new compounds that appear to be safer, but you don't know for sure until a drug is developed that you can give to patients," says Spiegelman.

Avandia and Actos are members of a drug class called thiazolidinediones (TZD) that have proven to be effective, oral diabetes drugs and are well tolerated by most patients. In a minority of patients, however, Avandia and Actos have been linked to cardiac complications, including fatal heart attacks and loss of bone density. The drugs are under close scrutiny by federal regulators, and are prescribed cautiously by physicians.

TZD drugs target a metabolic "master regulator" of fat cell development, called PPAR-gamma, which is a transcription factor controlling the behavior of a host of genes and proteins related to diabetes. Spiegelman's lab discovered the role of PPAR-gamma as a regulator of fat cell development in 1994. The new experimental compounds also target PPAR-gamma, but through a different mechanism discovered this past year.

Actos and Avandia are so-called "agonists" of PPAR-gamma. That is, they bind to the molecule, like a key fitting into a lock, and activate it. When activated, PPAR-gamma causes changes in an unknown number of "downstream" genes and proteins. This cascade treats diabetes by improving cells' response to insulin and helping the body to control blood sugar. However, the researchers believe this series of molecular events initiated by PPAR-gamma agonism also causes the harmful fluid retention, weight gain, and loss of bone density.

Until recently, it had been assumed that Avandia and Actos worked exclusively by agonizing PPAR-gamma. But in 2010, Spiegelman and Griffin reported that they had discovered a second, unsuspected effect of the drugs on PPAR-gamma. The TZD drugs, they said, also block a process called phosphorylation, by a molecule known as Cdk5, that modifies PPAR-gamma in a manner that is entirely separate from agonism. This mechanism, they said, might in fact be more critical to combating diabetes -- and, to their surprise, apparently seemed not to cause the worrisome side effects.

In the new report, the team describes the development of synthetic small molecules "that bind tightly to PPAR-gamma yet are completely devoid of classical agonism, and effectively inhibit phosphorylation."

These findings suggested that it might be possible to develop new diabetes drugs that work entirely by blocking the phosphorylation of PPAR-gamma, thus separating wanted from unwanted effects.

Griffin, who heads Scripps' Department of Molecular Therapeutics, and his team devised a plan for concocting the prototype drugs. They searched the literature for compounds known to bind with PPAR-gamma, and chose one to serve as a scaffold which they modified in hundreds of ways. The researchers sifted through these modifications until they found several that blocked phosphorylation of PPAR-gamma.

The most effective of these candidates, labeled SR1664, was tested in cultured cells and insulin-resistant mice in the Spiegelman laboratory. It was found to have potent anti-diabetic properties but caused no fluid retention or weight gain. When compared with Avandia, SR1664 showed equivalent anti-diabetic effects, confirming the scientists' hypothesis that diabetes can be treated by drugs that target PPAR-gamma but don't agonize the molecule.

These studies illustrate that the development of entirely new classes of PPAR-gamma-targeted drugs is feasible, concludes Spiegelman, who is the Stanley J. Korsmeyer Professor of Cell Biology and Medicine at Harvard Medical School, and his colleagues.

The co-first authors of the paper are Jang Hyun Choi, PhD, and Alexander Banks, PhD, in the Spiegelman lab.

Support for the research came from the National Institutes of Health.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jang Hyun Choi, Alexander S. Banks, Theodore M. Kamenecka, Scott A. Busby, Michael J. Chalmers, Naresh Kumar, Dana S. Kuruvilla, Youseung Shin, Yuanjun He, John B. Bruning, David P. Marciano, Michael D. Cameron, Dina Laznik, Michael J. Jurczak, Stephan C. Schürer, Dušica Vidović, Gerald I. Shulman, Bruce M. Spiegelman, Patrick R. Griffin. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature, 2011; DOI: 10.1038/nature10383

Cite This Page:

Dana-Farber Cancer Institute. "New twist in diabetes drugs could reduce life-threatening side effects." ScienceDaily. ScienceDaily, 9 September 2011. <www.sciencedaily.com/releases/2011/09/110909111523.htm>.
Dana-Farber Cancer Institute. (2011, September 9). New twist in diabetes drugs could reduce life-threatening side effects. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2011/09/110909111523.htm
Dana-Farber Cancer Institute. "New twist in diabetes drugs could reduce life-threatening side effects." ScienceDaily. www.sciencedaily.com/releases/2011/09/110909111523.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Possible Ebola Patient in Isolation at California Hospital

Possible Ebola Patient in Isolation at California Hospital

Reuters - US Online Video (Aug. 20, 2014) — A patient who may have been exposed to the Ebola virus is in isolation at the Kaiser Permanente South Sacramento Medical Center. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Raw: World's Oldest Man Lives in Japan

Raw: World's Oldest Man Lives in Japan

AP (Aug. 20, 2014) — A 111-year-old Japanese was certified as the world's oldest man by Guinness World Records on Wednesday. Sakari Momoi, a native of Fukushima in northern Japan, was given a certificate at a hospital in Tokyo. (Aug. 20) Video provided by AP
Powered by NewsLook.com
Do More Wedding Guests Make A Happier Marriage?

Do More Wedding Guests Make A Happier Marriage?

Newsy (Aug. 20, 2014) — A new study found couples who had at least 150 guests at their weddings were more likely to report being happy in their marriages. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) — Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

More Coverage


New Class of Anti-Diabetic Compound Established

Sep. 4, 2011 — Scientists have established a new class of anti-diabetic compound that targets a unique molecular ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins